Search Results
Mar 24, 2026, 09:15 ET Appdome Introduces Vault™, a Searchable Source of Truth for Mobile Security and Fraud Compliance
actionsSecurity, fraud, bot, and API protection policy configurationsBuild and release metadata from CI/CD pipelinesCertified Secure™ certificates and watermarkingWorkspace and administrative changesChange approvals and governance
More news about: Appdome
Mar 24, 2026, 09:00 ET Assail Launches Ares, the First Autonomous Red Team Platform Purpose-Built for the Modern Application Stack
required.Continuous Exposure Management: Replaces the point-in-time penetration test with always-on autonomous red teaming that keeps pace with modern CI/CD deployment cycles, shrinking exposure windows from weeks to minutes.About the FounderAlissa Knight is a 26-year offensive
More news about: Assail, Inc.
Mar 24, 2026, 07:44 ET WuXi Biologics Reports Record 2025 Annual Results
securing potential milestone and royalties over US$4 billion.CD3 T-cell engager (TCE) partnerships continued to expand during the year, reflecting growing industry adoption of the Group's leading CD3 platform. The platform has been adopted by many leading biopharma companies, including
More news about: WuXi Biologics
Mar 24, 2026, 07:00 ET Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Met First Co-Primary Endpoint, Demonstrating Statistically Significant Improvement in Spleen Volume Reduction
at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti‐CD38 monoclonal antibody (Xd).For the treatment of adult patients with relapsed or refractory diffuse large B‐cell lymphoma (DLBCL),
More news about: Karyopharm Therapeutics Inc.
Mar 24, 2026, 04:45 ET IASO Bio Has Received Clearance from Japan's PMDA to Initiate Clinical Trial for CAR-T Therapy Equecabtagene Autoleucel in Second- or Third-Line Multiple Myeloma
anti-BCMA CAR-T cell therapy which uses lentivirus vector to transfect autologous T cells. The CAR contains a fully human scFv, CD8a hinge and transmembrane, 4-1BB co-stimulatory and CD3ζactivation domains. Based on rigorous molecular structure screening and comprehensive in vitro and in vivo functional evaluations,
More news about: IASO Bio
Mar 24, 2026, 04:00 ET MSI Highlights Cloud, AI, and Enterprise Server Platforms at CloudFest 2026
CD270-S3071-X4 is a 2U 4-node platform designed for high-density cloud deployments. Each node supports a single Intel Xeon 6 processor (up to 400W TDP) with
More news about: Micro-Star INT'L CO., LTD.
Mar 24, 2026, 04:00 ET MSI Highlights Cloud, AI, and Enterprise Server Platforms at CloudFest 2026
CD270-S3071-X4 is a 2U 4-node platform designed for high-density cloud deployments. Each node supports a single Intel Xeon 6 processor (up to 400W TDP) with
More news about: Micro-Star INT'L CO., LTD.
Mar 24, 2026, 04:00 ET Cloud Native Computing Foundation Announces Kyverno's Graduation
Argo CD,
More news about: Cloud Native Computing Foundation
Mar 24, 2026, 04:00 ET CNCF and SlashData Report Finds Platform Engineering Tools Maturing as Organizations Prepare for AI-Driven Infrastructure
developers claiming that they would recommend it to peers.Jenkins demonstrated strong maturity scores, reflecting its long standing role in CI/CDDevelopers gave Karmada and other newer tools high maturity ratings. Karmada achieved the highest usefulness rating among workflow automation
More news about: Cloud Native Computing Foundation
Mar 24, 2026, 04:00 ET MSI met à l'honneur le cloud, l'IA et les plateformes de serveurs d'entreprise au CloudFest 2026
CD270-S3071-X4 est une plateforme 2U quadrinœuds conçue pour les déploiements cloud à haute densité. Chaque nœud prend en charge un processeur Intel Xeon 6
More news about: Micro-Star INT'L CO., LTD.
Mar 23, 2026, 08:33 ET What's Driving the Shift Toward Short‑Term Promo CDs? CD Valet Analyzes Market Behavior Following Latest Federal Reserve Meeting
costs."About CD Valet CD Valet is a CD marketplace that features verified CD rates from federally insured banks and credit unions. With tens of thousands of CD offers tracked across the country, CD Valet gives savers a clear view of top rates and helps them explore high-yield CD options with
More news about: CD Valet
Mar 23, 2026, 08:00 ET Invicti Tops in Independent DAST Benchmark Tests
application frontends and APIs. With its best-of-breed dynamic application security testing (DAST) acting as the fact-checker, Invicti integrates into CI/CD pipelines to deliver proof-based results supported by AI-powered prioritization and remediation. Built on more than 20 years of DAST innovation through
More news about: Invicti Security
Mar 23, 2026, 08:00 ET Gomboc Expands Beyond IaC with ORL to Deliver Deterministic Remediation Cloud and Code
rules, ORL evaluates them, and Gomboc applies governed, repeatable changes. Fixes are delivered as merge-ready pull requests through existing Git and CI/CD workflows.This approach ensures that remediation is:DeterministicScalable across teams and repositoriesAligned
More news about: Gomboc AI
Mar 23, 2026, 08:00 ET Cisco Reimagines Security for the Agentic Workforce
outputs.Straightforward Security Reporting: Get actionable AI security insights, exportable for compliance review.API-First Access: Tap into CI/CD integration for GitHub Actions, GitLab, Jenkins, and custom pipelines.Team Collaboration: Invite teammates; upgrade to AI Defense Enterprise
More news about: Cisco Systems, Inc.
Mar 23, 2026, 08:00 ET Cisco Reimagines Security for the Agentic Workforce
outputs.Straightforward Security Reporting: Get actionable AI security insights, exportable for compliance review.API-First Access: Tap into CI/CD integration for GitHub Actions, GitLab, Jenkins, and custom pipelines.Team Collaboration: Invite teammates; upgrade to AI Defense Enterprise
More news about: Cisco Systems, Inc.
Mar 23, 2026, 07:01 ET Kali Therapeutics Announces Worldwide Exclusive License Agreement with Sanofi for Next-Generation Tri-Specific T-Cell Engager for Autoimmune Diseases
tri-specific T-cell engager designed to bind CD3, CD19, and BCMA with high affinity, thereby targeting a broad range of B cell populations. Utilizing an innovative molecular design aimed at maximizing potency while minimizing cytokine release via a unique CD3 masking platform, KT501 has demonstrated potent
More news about: Kali Therapeutics
Mar 23, 2026, 07:00 ET BioLineRx Reports 2025 Financial Results and Provides Corporate Update
NCT05618301) evaluating motixafortide as monotherapy and in combination with natalizumab for CD34+ hematopoietic stem cell (HSC) mobilization for gene therapies in sickle cell disease (SCD) was presented at the 67th American Society of Hematology
More news about: BioLineRx Ltd.
Mar 23, 2026, 06:45 ET Sealed Air Announces Completion of Regulatory Approvals for Acquisition by CD&R
SEE) today announced that it has received all regulatory approvals required to complete the Company's pending acquisition by funds affiliated with CD&R. The transaction is expected to close in April 2026, subject to the satisfaction of remaining customary closing conditions.
More news about: Sealed Air
Mar 23, 2026, 04:00 ET OpenSSF Celebrates New Members, No-Cost Tooling, and Project Milestones
architecture, platform engineering, and DevSecOps. Open source components are foundational to modern infrastructure from Kubernetes and IaC tooling to CI/CD pipelines and security automation. Strengthening this ecosystem requires measurable standards, robust software supply chain security practices, and active
More news about: OpenSSF
Mar 20, 2026, 10:00 ET Data from Phase 2b Studies for Rezpegaldesleukin Accepted for Two Oral Presentations at the 2026 American Academy of Dermatology Annual Meeting
Rezpegaldesleukin works by targeting the IL-2 receptor complex and preferentially stimulating the proliferation of Treg cells without stimulating cytotoxic CD8+ T and CD4+ T cells, which drive autoimmune disease, to restore immune balance.Details of the presentations at AAD are as follows:Late-Breaking
More news about: Nektar Therapeutics
Mar 20, 2026, 09:03 ET 復宏漢霖2025年業績：收入利潤持續雙增長，體系出海加速落地，創新管線進入密集驗證期
Club平台在內的多維技術平台。業績期內，HLX37（PD-L1 x VEGF雙抗）、HLX97（KAT6A/B小分子抑制劑）、HLX3901（DLL3 x DLL3 x CD3 x CD28四抗TCE）、HLX316（B7-H3唾液酸酶融合蛋白）等分子獲得新藥臨床試驗批准。同時，公司持續推進多款潛力候選分子研發，包括HLX3902（STEAP1 x CD3 x CD28三抗TCE）、HLX48（EGFR x cMET雙抗ADC）、HLX49（HER2雙表位ADC）、HLX109（IL-1R3單抗）等，持續豐富具備全球競爭力的創新管線。作為全球化2.0的重
More news about: 復宏漢霖
Mar 20, 2026, 09:03 ET Henlius Reports 2025 Results: Sustained Growth in Both Revenue and Profit, Advancing Innovation Validation and Global Operations
inhibitor), HLX3901 (DLL3 × DLL3 × CD3 × CD28 tetra-specific TCE), and HLX316 (B7-H3 sialidase fusion protein)—received Investigational New Drug (IND) approvals. Meanwhile, the Company continues to advance a number of promising pipeline assets, including HLX3902 (STEAP1 × CD3 × CD28 tri-specific TCE), HLX48
More news about: Henlius
Mar 20, 2026, 05:06 ET Antengene Announces 2025 Full-Year Results: First TCE Out-licensing Validates Platform Value and Marks Inflection Point Towards 2026 Profitability
UCB), CDH6 x CD3 (ATG-106 for ovarian cancer and kidney cancer), ALPPL2 x CD3 (ATG-112 for gynecological tumors, digestive system malignancies, bladder cancer and NSCLC), LY6G6D x CD3 (ATG-110 for microsatellite-stable colorectal cancer), GPRC5D x CD3 (ATG-021 for multiple myeloma), LILRB4 x CD3 (ATG-102
More news about: Antengene Corporation Limited
Mar 19, 2026, 21:29 ET GI Innovation Announces First Clinical Supply Agreement to Explore Combination Therapy for Prostate Cancer
This trial aims to evaluate the combination of GI Innovation's immuno-oncology agent GI-102 with pasritamig (KLK2-CD3), a first-in-class bispecific T-cell engager. This trial will explore the therapeutic potential of the combination regimen in patients with mCRPC,
More news about: GI Innovation
Mar 19, 2026, 16:06 ET Cyberify Unveils QuantumReady™
verified hybrid states if a PQC module fails.Automated Discovery & CBOM Generation: Performs packet inspection and scans web servers, ci/cd orchestrators and other source code to generate a Cryptographic Bill of Materials (CBOM).Compliance & Risk Visualization: Features
More news about: Cyberify Inc.